title: [Effect of sphingosine-1-phosphate on chemotherapy-induced ovarian damage and on the efficacy of chemotherapy in mice bearing S180 tumor].
abstract: OBJECTIVE
  To investigate the effects of sphingosine-1-phosphate (S1P) on cyclophosphamid (CTX) and cisplatin (DDP)-induced ovarian damage and on the efficacy of chemotherapy in mice bearing S180 murine sarcoma.
  
  
  METHODS
  Fifty-two female C57BL/6 mice were randomized into normal control group (n=10), tumor-bearing model group (n=14), CTX+DDP group (n=14), and S1P+CTX+DDP group (n=14). Before medication and on day 11 of medication during diestrus stage, the mice were sacrificed to measure the ovarian weight, numbers of primordial follicles and growing follicles, tumor weight, and serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol ( E2).
  
  
  RESULTS
  At day 11 of medication, the levels of serum FSH and E2, but not LH, showed significant differences in CTX+DDP group from those in the other groups (P<0.01). FSH, E2, and LH levels were comparable between S1P+CTX+DDP group and the control group (P>0.05). The number of primodial follicles and weight of ovaries in CTX+DDP group decreased significantly compared to those in the other groups (P<0.01). The number of growing follicles in CTX+DDP group was significantly lower than that in the control and model groups(P<0.01), but similar to that in S1P group (P>0.05). The number of primodial follicles and growing follicles and ovarian weight in S1P+CTX+DDP group were close to those in the control and model groups (P>0.05). In CTX+DDP and S1P+CTX+DDP groups, the tumor weight were significantly lower than that in the other two groups (P<0.01), and the tumor inhibition rates were both higher than 60%.
  
  
  CONCLUSIONS
  S1P can ameliorate chemotherapy-induced ovarian damage in mice without affecting the efficacy of chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou 510010, China. pengping1967@yahoo.com.cn
authors.forename: Ping
authors.initials: P
authors.lastname: Peng
authors.forename: Xuan
authors.initials: X
authors.lastname: Wu
authors.forename: Ting
authors.initials: T
authors.lastname: Guan
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Yan-Ling
authors.initials: YL
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Chuan-Hong
authors.initials: CH
authors.lastname: Yang
authors.forename: Chang-Lan
authors.initials: CL
authors.lastname: Ye
authors.forename: Shan-Lin
authors.initials: SL
authors.lastname: Wang
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D008246:Lysophospholipids / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced* / Q000517:prevention & control*; D012510:Sarcoma 180 / Q000188:drug therapy*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D008246:Lysophospholipids; C060506:sphingosine 1-phosphate; D003520:Cyclophosphamide; D013110:Sphingosine; D002945:Cisplatin